Tata Capital Healthcare Fund II Invests $20 Million In Orbicular Pharmaceutical Technologies

Tata Capital Healthcare Fund II (TCHF II), the healthcare-focused private equity fund of Tata Capital, has committed approximately USD 20 million to Orbicular Pharmaceutical Technologies. In a press statement on Saturday, the company informed that this Hyderabad-based speciality pharmaceutical company specialises in developing complex generics for global markets. The investment, in exchange for an undisclosed equity stake, is set to expedite Orbicular's product pipeline development, the statement added.

The speciality generics industry, with a market size exceeding USD 60 billion, is rapidly growing due to the rising demand for affordable alternatives to complex and expensive branded medications. Orbicular has established a robust pipeline of niche products within this space, making it an attractive partner for global generic companies targeting regulated markets.

Visalakshi Chandramouli, Managing Partner at Tata Capital Healthcare Fund, expressed excitement about the partnership: “We are thrilled to partner with Orbicular, which leads in R&D for complex generics. Under Dr M.S. Mohan’s leadership, Orbicular has built a strong pipeline for regulated markets. We are proud to support their dynamic team and be part of their growth journey. This investment aligns with our fund’s philosophy of identifying significant industry shifts and being a 'capital plus' partner.”

Dr M.S. Mohan, Managing Director of Orbicular, highlighted the significance of this investment: “Today marks a transformative milestone for us. Starting as a bootstrapped company to now being backed by Tata Capital Healthcare Fund, we are positioned as a differentiated speciality pharmaceutical company in the complex generics space. This investment will enhance our global partnerships. I am proud of our team’s achievements and together, we will drive differentiation, advance healthcare solutions, and positively impact millions worldwide.”

Dr Hiren Patel, Chief Executive Officer of Orbicular, emphasised the partnership’s impact: “This new collaboration with Tata Capital Healthcare Fund affirms our capabilities and will accelerate our R&D efforts, expand our portfolio, and strengthen our global partnerships.”

Ambit acted as the exclusive financial advisor to Orbicular and its shareholders during this transaction. Vikas Khattar, MD, Co-Head Investment Banking and Head - ECM at Ambit, along with Ritesh Desai, Executive Director – Pharma and Healthcare Investment Banking, played pivotal roles in facilitating this partnership.